| Prev Close | 86.44 |
| Open | 86.92 |
| Day Low/High | 86.21 / 86.95 |
| 52 Wk Low/High | 62.66 / 92.99 |
| Volume | 7.82M |
| Avg Volume | 7.67M |
AbbVie Inc. (ABBV)
86.97
0.53
0.61
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 127.83B |
| EPS | 3.70 |
| P/E Ratio | 37.91 |
| Div & Yield | 4.72 (4.92%) |
8 Beaten-Down Post-Brexit Bargains
These names are now oversold and are sitting at attractive prices.
Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study
Analysts cut valuation estimates after a disappointing drug study.
Why Adding AbbVie Is the Pill to Take
With the recent pullback in the stock price, AbbVie is an attractive buy.
Tweets on the Street: Investing in Fitness Innovation; Market Volatility Spikes
Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.
AbbVie Gears Up for an Even Higher Run
Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.
Cramer: Many Portfolio Managers Hope for the 'Wrong' Jobs Number
This is because they would buy more of the winning stocks lower.
Biotech M&A Waking Up After Long Nap
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
3 Small Biotechs Make Some Noise on a Quiet Day
The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today. Aratana Therapeutics (PETX) is up 7% today. Ther...
Remain Patient in This Sideways Market
Keep cash on hand and be ready for oportunities as they arise.
2 Big -- and Mispriced -- Biotech Stocks
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
2 Portfolios for the Fundamentally Sound
We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.
Trending Tickers: HD, P, ABBV, ODP, LC
Home Depot shares were falling despite a strong first-quarter showing.
Biotech Is Showing Some Bargains
It is hard to see much growth in the market overall, until earnings growth returns.
This Was One Dismal Earnings Season
And it's hard to get excited about the second quarter, too.
Biotech Is Ripe for M&A: Analysts
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
2016 Sohn Investment Conference Live Blog: Session 1
Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.
Sohn Preview: What Will Larry Robbins, John Khoury & Carson Block Present Wednesday?
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.
Cramer: Worst May Be Over for Embattled Pharma
The M&A activity is an incredible and a welcome sign.
Will Poor Earnings Bring Down the Market?
This earnings season continues to disappoint, and technology names are leading the downward charge.
Some Stocks Are Really Cheap
There are lots of winners in the first quarter.
Value, Yield a Must in 'Wade Boggs' Market
It's important to focus on hitting singles in this overbought and earnings-starved environment.
9 Health Names to Like Amid the Rhetoric
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
What Earnings Season Shows So Far
This will still be fourth quarter in a row that profits have declined year over year.
U.S. Futures Rise as Markets Look to Reverse Monday's Decline
U.S. indices look to reverse yesterday's losses as crude prices continue their climb.
3 Biotech Stocks to Buy Right Now
With low multiples and solid yields, these names look good for the long term.
AbbVie Is Rx for a Volatility Squeeze
ABBV is rising, and the current action could be the start of a strong move higher.
6 Stocks To Pick Up for the 2nd Quarter
In this choppy market, the sweet spot is large-caps with these three core attributes.
A Small Biotech Sells for Less Than Cash
And yet, Endocyte has a deep pipeline.
Biotech Stocks Are Beginning to Stir
I am starting to get more confident that the small caps are ready to bounce.
